Alpha-1-antitrypsin deficiency

Seminars in Liver Disease

Volumn 18, Issue 3, 1998, Pages 217-225

  Perlmutter, David H ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

Emphytsema; Endoplasmic reticulum retention; Metabolic liver disease; 1 Antitrypsin deficiency

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALNEXIN; LEUKOCYTE ELASTASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC LIVER DISEASE; CLINICAL FEATURE; ENDOPLASMIC RETICULUM; GENE THERAPY; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG EMPHYSEMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031694568     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007158     Document Type: Review

References (64)

1. Sveger T. Liver disease in α1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-1321
2. Sveger T, Eriksson S. The liver in adolescents with α1-antitrypsin deficiency. Hepatology 1995;22:514-517
3. Ibarguen E, Gross CR, Savik SK, Sharp HL. Liver disease in α1-antitrypsin deficiency: prognostic indicators. J Pediatr 1990; 117:864-870
4. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in α1-antitrypsin deficiency. N Engl J Med 1986; 314:736-739
5. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W. High prevalence of viral infections in adults with homozygous and heterozygous α1-antritrypsin deficiency and chronic liver disease. Ann Intern Med 1992;117:641-645
6. Long GL, Chandra T, Woo SLC, Davie EW, Kurachi K. Complete nucleotide sequence of the cDNA for human α1-antitrypsin and the gene for the S variant. Biochemistry 1984;23:4828-4837
7. Perlino E, Cortese R, Ciliberto G: The human α1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. EMBO J 1987;6:2767-2771
8. Hafeez W. Ciliberto G, Perlmutter DH. Constitutive and modulated expression of the human α1-antitrypsin gene: Different transcriptional initiation sites used in three different cell types. J Clin Invest 1992;89:1214-1222
9. Huber R, Carrell RW. Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins. Biochemistry 1990;28:8951-8956
10. Brantly M, Lee JH, Hildeshiem J, et al. α1-antitrypsin gene mutalion hot spot associated with the formation of a retained and degraded null variant Am J Respir Cell Mol Biol 1997,16: 225-231
11. Muensch H, Gaidulis L, Kueppers F, et al Complete absence of serum alpha-1-antitrypsin in conjunction with an apparently normal gene structure. Am J Hum Genet 1986;38:898-907
12. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin: α1-antitrypsin Pittsburgh (358 Met - Arg), a fatal bleeding disorder, N Engl J Med 1983;309:694-698
13. Crystal RG. Alpha-1-antitrysin deficiency, emphysema and liver disease: genetic basis and strategies for therapy. J Clin Invest 1990;95:1343-1352
14. Reid CL, Wiener GJ, Cox DW, Richter JE, Geisinger KR. Diffuse hepatocellular dysplasia and carcinoma associated with the Mmalton variant of α1-antitrypsin. Gastroenterol 1987;93:181-1187
15. malton. J Biol Chem 1989;264:13938-13945
16. duarte. Gastroenterol 1987;93:242-244
17. Hyama (senne 53 (TCC) to phenylalanine 53 (TTC): A new α1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991; 266:12627-12632
18. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655-709
19. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 1977;116:469-475
20. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type α1-antitrypsin is less competent than M1-type α1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;89: 1366-1374
21. Hood JM, Koep LJ, Peters RL, et al. Liver transplantation for advanced liver disease with α1-antitrypsin deficiency. N Engl J Med 1980;302:272-276
22. 2/interleukin-6 modulates synthesis of β1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest 1989; 264:9485-9490
23. Laurell C-B, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens. J Clin Endocrinol Metab 1979;49:719-725
24. Povey S. Genetics of α1-antitrypsin deficiency in relation to neonatal liver disease. Mol Biol Med 1990;7:161-162
25. Lobo-Yeo A, Senaldi G, Portmann R, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: A study in children with liver disease. Hepatology 1990;12:224-232
26. Dycaico JM, Grant SGN, Felts K, et al. Neonatal hepatitis induced by α1-antitrypsin: a transgenic mouse model Science 1988;242:1404-1412
27. Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of PiZ antitrypsin causes liver damage in transgenic mice. J Clin Invest 1988;83:1183-1190
28. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. A lag in intracellular degradation of mutant α1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ α1-antitrypsin deficiency. Proc Natl Acad Sci USA 1994;91:9014-9018
29. Perlmutter DH, Kay RM, Cole FS, Rossing TH, Van Thiel D, Colten HR. The cellular defect in α1-proteinase inhibitor deficiency is expressed in human monocytes and xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci USA 1985;82:6918-6921
30. Brantly M, Courtney M, Crystal RG. Repair of the secretion of defect in the Z form of α1-antitrypsin by addition of a second mutation. Science 1988;242:1700-1702
31. McCracken AA, Kruse KB, Brown JL. Molecular basis for defective secretion of variants having altered potential for salt bridge formation between amino acids 240 and 242. Mol Cell Biol 1989;9:1408-1414
32. Sifers RN, Hardick CP, Woo SLC. Disruption of the 240-342 salt bridge is not responsible for the defect of the PIZ α1-antitrypsin variant. J Biol Chem 1989;264:2997-3001
33. Wu Y, Foreman RC. The effect of amino acid substitutions at position 342 on the secretion of human α1-antitrypsin from xenopus oocytes FEBS Lett 1990,268:21-23
34. Lomas DA, Evans DL, Finch JJ, Carrell RW. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992;357: 605-607
35. Yu M-H, Lee KN, Kim J. The Z type variation of human α1-antitrypsin causes a protein folding defect. Nat Struct Biol 1995; 2:363-367
36. Rothman JE, Wieland FT. Protein sorting by transport vesicles. Science 1996;272:227-234
37. Bergeron JJM, Brenner MB, Thomas DY, Williams DB. Calnexin A membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem Sci 1994;19:124-128
38. Ou W-J, Cameron PH, Thomas DY, Bergeron JJM. Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature 1993;364;771-776
39. Sousa MC, Ferrero-Garcia MA, Parodi AJ. Recognition of the oligosaccharide and protein moieties of glycoproteins by the UDP-glucose:glycoprotein glucosyl-transferase. Biochemistry 1992;31:97-105
40. Hebert DN, Foellmer B, Helenius A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 1995;81:425-453
41. Bonifacino JS, Suzuki CK, Lippincott-Schwartz J, Weissman AM, Klausner RD. Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. J Cell Biol 1989;109:73-83
42. Choudhury P, Liu Y, Bick RJ, Sifers RN. Intracellular association between UDP-glucose: glycoprotein glucosyltransferase and an incompletely folded variant of α1-antitrypsin. J Biol Chem 1997;272:13446-13451
43. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-protcasome pathway. Cell 1995;83:121-127
44. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995;83:129-135
45. Qu D, Teckman TH, Omura S, Perlmuter DH. Degradation of mutant secretory protein, α1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996;271: 22791-22795
46. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992;61:761-807
47. Werner ED, Brodsky JL, McCracken AA. Proteasome-dependent endoplasmic reticulum-associated protein degradation: An unconventional route to a familiar fate. Proc Natl Acad Sci USA 1996;93:13797-13801
48. 1-antitrypsin involves release from calnexin and post-translational trimming of asparagine-linked oligosaccharides. J Biol Chem 1997;272:7946-7951
49. Wiertz EJHJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384:432-438
50. McCracken AA, Brodsky JL. Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J Cell Biol 1996;131:291-298
51. Hiller MM, Finger A, Schweiger M, Wolf DH ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 1996;273:1725-1728
52. Plemper RK, Bohmler S, Bordallo J, Sommer T, Wolf DH. Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation. Nature 1997;388:891-895
53. Geller SA, Nichols WS, Kim SS, et al. Hepatocarcinogenesis is the sequel to hepatitis in Z #2 α1-antitrypsin transgenic mice: histopathological and DNA ploidy studies. Hepatology 1994; 19:389-397
54. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995;22:1317-1325
55. Raposo G, van Santen HM, Liejendekker R, Geuze HJ, Ploegh HL. Misfolded major histocompatibility complex class I molecules accumulate in an expanded ER-Golgi intermediate compartment. J Cell Biol 1995;131:1403-1419
56. Dunn WA. Studies on the mechanism of autophagy: formation of autophagic vacuole. J Cell Biol 1991;110:1923-1933
57. Sidrauski C, Cox S, Walter P. tRNA ligase is required for regulated mRNA splicing in the unfolded protein response. Cell 1996;87:405-413
58. Cox JS, Walter P. A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response. Cell 1996;87:391-404
59. Pahl HL, Sester M, Gurgert H-G, Baeuerle PA. Activation of transcription factor NK-κB by the adenovirus E3/19K protein requires its ER retention. J Cell Biol 1996;132:511-522
60. Perlmutter DH, Schlesinger MJ, Pierce JA, Punsal PI, Schwartz AL. Synthesis of stress proteins is increased in individuals with homozygous PiZZ α1-antitrypsin deficiency and liver disease. J Clin Invest 1989;84:1555-1561
61. Casavilla FA, Reyes J, Tzakis A, et al. Liver transplantation for neonatal hepatitis as compared to the other two leading indications for liver transplantation in children Hepatology 1994;21: 1035-1039
62. Castanotto D, Rossi JJ, Sarver N. Antisense catalytic RNAs as therapeutic agents. Adv Pharmacol 1994;25:289-317
63. Rhim JA, Sandgen EP, Degen JL, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994;263:1149-1152
64. Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996;12:266-273